These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32893157)

  • 1. Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: Insights From a Network Meta-Analysis of Randomized Trials.
    Kuno T; Ueyama H; Takagi H; Fox J; Bangalore S
    Cardiovasc Revasc Med; 2021 Jul; 28():50-56. PubMed ID: 32893157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; Frati G; Biondi-Zoccai G; De Luca G
    J Thromb Thrombolysis; 2020 Aug; 50(2):337-354. PubMed ID: 31919736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.
    Yin SH; Xu P; Wang B; Lu Y; Wu QY; Zhou ML; Wu JR; Cai JJ; Sun X; Yuan H
    BMJ; 2019 Jun; 365():l2222. PubMed ID: 31253632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of short-term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Misumida N; Abo-Aly M; Kim SM; Ogunbayo GO; Abdel-Latif A; Ziada KM
    Clin Cardiol; 2018 Nov; 41(11):1455-1462. PubMed ID: 30225978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Outcomes Evaluation After Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short- Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-analysis of Randomized Control Trials.
    Bhattarai M; Ibrahim AM; Salih M; Tandan N; Al-Akchar M; Ayan M; Kulkarni A; Hafiz AM
    J Cardiovasc Pharmacol; 2020 Nov; 76(5):574-583. PubMed ID: 33165135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short Duration vs Standard Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents - A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials.
    Wassef AW; Khafaji H; Syed I; Yan AT; Udell JA; Goodman SG; Cheema AN; Bagai A
    J Invasive Cardiol; 2016 Dec; 28(12):E203-E210. PubMed ID: 27630146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
    Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials.
    Kheiri B; Simpson TF; Osman M; Golwala H; Radaideh Q; Kumar K; Rahmouni H; Divanji P; Cigarroa JE; Zahr F
    J Thromb Thrombolysis; 2020 Nov; 50(4):867-873. PubMed ID: 32607653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
    Palmerini T; Della Riva D; Benedetto U; Bacchi Reggiani L; Feres F; Abizaid A; Gilard M; Morice MC; Valgimigli M; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Colombo A; Chieffo A; Sangiorgi D; Biondi-Zoccai G; Généreux P; Angelini GD; Pufulete M; White J; Bhatt DL; Stone GW
    Eur Heart J; 2017 Apr; 38(14):1034-1043. PubMed ID: 28110296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
    Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
    Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial.
    Kedhi E; Verdoia M; Suryapranata H; Damen S; Camaro C; Benit E; Barbieri L; Rasoul S; Liew HB; Polad J; Ahmad WA; Zambahari R; Lalmand J; van der Schaaf RJ; Koh TH; Timmermans P; Dilling-Boer D; Veenstra LF; Van' T Hof AW; Lee SW; Roolvink V; Ligtenberg E; Postma S; Kolkman EJ; Brouwer MA; Dudek D; De Luca G
    Atherosclerosis; 2021 Mar; 321():39-44. PubMed ID: 33639478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
    Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
    Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy and Safety of Duration of Dual Antiplatelet Therapy in Patients with CAD Undergoing Drug-eluting Stent Implantation: A Systematic Review and Network Meta-analysis.
    Guan J; Song W; He P; Fan S; Zhi H; Wang L
    Curr Pharm Des; 2020; 26(44):5739-5745. PubMed ID: 32586248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials.
    Verdoia M; Khedi E; Ceccon C; Suryapranata H; De Luca G
    Int J Cardiol; 2018 Aug; 264():30-38. PubMed ID: 29776573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
    Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
    Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
    Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
    Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term dual antiplatelet therapy in diabetic patients admitted for acute coronary syndrome treated with a new-generation drug-eluting stent.
    Vranken NPA; Rasoul S; Luijkx JJP; Pustjens TFS; Postma S; Kolkman EJ; Kedhi E; Rifqi S; Lee MKY; Ebelt H; Merkely B; Verdoia M; Wojakowski W; van 't Hof AAWJ; Suryapranata H; De Luca G
    Diabetes Metab Res Rev; 2022 Jul; 38(5):e3530. PubMed ID: 35395144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Selvaraj V; Chatterjee S; Hirai T; Abbott JD; Bavishi C
    Catheter Cardiovasc Interv; 2022 Dec; 100(7):1151-1158. PubMed ID: 36326115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term vs long-term dual antiplatelet therapy after drug-eluting stent implantation in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Int J Clin Pract; 2021 Jul; 75(7):e13938. PubMed ID: 33341109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.